title: Transport for abciximab facilitated primary angioplasty versus on-site thrombolysis with a liberal rescue policy: the randomised Holland Infarction Study (HIS).
abstract: OBJECTIVE
  As of to date, the only large transportation trial comparing on-site fibrin-specific thrombolysis with transfer for primary angioplasty in patients presenting in a referral centre is the DANAMI-2 trial, with only 3% rescue angioplasty. The Holland Infarction Study (HIS) compared abciximab facilitated primary angioplasty (FP) with on-site fibrin-specific thrombolytic therapy (TT) with a liberal protocol-driven rescue angioplasty (transport to intervention centre in case < 50% ST resolution at 60 min).
  
  
  RESULTS
  Patients in a referral centre without shock and < 4.5 h of chest pain presenting with ST-elevation having > or = 12 mm ST-segment shift were randomised to either strategy. Of the originally planned 900 patients only 48 were included due to suspension of financial funding. Death, recurrent MI and stroke at one year was 8% for the FP-group and 22% for the TT-group (p = 0.2). Two hours after randomisation the rates of complete ST-segment resolution (> or =70%) were 52% and 35%, respectively (p = 0.2).
  
  
  CONCLUSIONS
  This prematurely discontinued randomised transportation trial shows favorable trends with respect to long-term clinical outcome and early ST-resolution for abciximab facilitated primary angioplasty. In view of the real world delays associated with interhospital transport for primary angioplasty, treatment strategies focusing on early fibrin-specific lysis with a liberal selective rescue policy are warranted.
authors.affiliation: Department of Cardiology, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands. h.dieker@cardio.umcn.nl
authors.forename: Hendrik-Jan
authors.initials: HJ
authors.lastname: Dieker
authors.forename: Elvira V
authors.initials: EV
authors.lastname: van Horssen
authors.forename: Ferry M R J
authors.initials: FM
authors.lastname: Hersbach
authors.forename: Marc A
authors.initials: MA
authors.lastname: Brouwer
authors.forename: Ad J
authors.initials: AJ
authors.lastname: van Boven
authors.forename: Arnoud W J
authors.initials: AW
authors.lastname: van 't Hof
authors.forename: Wim R M
authors.initials: WR
authors.lastname: Aengevaeren
authors.forename: Freek W A
authors.initials: FW
authors.lastname: Verheugt
authors.forename: Frits W H M
authors.initials: FW
authors.lastname: Bär
mesh_terms: D000077284:Abciximab; D000368:Aged; D017130:Angioplasty; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy / Q000401:mortality / Q000601:surgery; D009426:Netherlands; D017063:Outcome Assessment, Health Care; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D015912:Thrombolytic Therapy / Q000401:mortality; D014187:Transportation of Patients; D017211:Treatment Failure
chemical_list: D000911:Antibodies, Monoclonal; D005343:Fibrinolytic Agents; D007140:Immunoglobulin Fab Fragments; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000077284:Abciximab